0 CHECKOUT

Brain Injury - Pipeline Review, H2 2015

  • ID: 3384917
  • July 2015
  • 47 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • Acorda Therapeutics, Inc.
  • Biogen, Inc.
  • Chiesi Farmaceutici SpA
  • Faron Pharmaceuticals Oy
  • FibroGen, Inc.
  • Virogenomics, Inc.
  • MORE

Brain Injury - Pipeline Review, H2 2015

Summary

The report ‘Brain Injury - Pipeline Review, H2 2015’, provides an overview of the Brain Injury’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Brain Injury, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Brain Injury and special features on late-stage and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles READ MORE >

Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • Acorda Therapeutics, Inc.
  • Biogen, Inc.
  • Chiesi Farmaceutici SpA
  • Faron Pharmaceuticals Oy
  • FibroGen, Inc.
  • Virogenomics, Inc.
  • MORE

List of Tables
List of Figures
Introduction
REPORT COVERAGE
Brain Injury Overview
Therapeutics Development
Pipeline Products for Brain Injury - Overview
Pipeline Products for Brain Injury - Comparative Analysis
Brain Injury - Therapeutics under Development by Companies
Brain Injury - Therapeutics under Investigation by Universities/Institutes
Brain Injury - Pipeline Products Glance
Early Stage Products
Brain Injury - Products under Development by Companies
Brain Injury - Products under Investigation by Universities/Institutes
Brain Injury - Companies Involved in Therapeutics Development
Acorda Therapeutics, Inc.
Biogen, Inc.
Chiesi Farmaceutici SpA
Faron Pharmaceuticals Oy
FibroGen, Inc.
Virogenomics, Inc.
Brain Injury - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Drug Profiles
Enzyme to Inhibit Chondroitin Sulfate Proteoglycan for Spinal Cord Injury and Brain Injury - Drug Profile
Product Description
Mechanism of Action
R&D Progress
FG-4497 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
interferon beta-1a - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Peptide to Inhibit Pannexin-1 for Brain Injury - Drug Profile
Product Description
Mechanism of Action
R&D Progress
PRE-084 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Recombinant Interleukin-34 to Agonize GM-CSFR for Alzheimer's Disease and Brain Injury - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Recombinant Protein to Agonize GM-CSFR for Alzheimer's Disease and Brain Injury - Drug Profile
Product Description
Mechanism of Action
R&D Progress
RTL-551 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Block TRPC3 for Acute Brain Injury - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Small Molecules to Inhibit Caspase-2 for Neonatal Brain Injury - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Synthetic Peptide to Inhibit Factor II for Thrombosis, Restenosis and Brain Injury - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Brain Injury - Recent Pipeline Updates
Brain Injury - Dormant Projects
Brain Injury - Discontinued Products
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products under Development for Brain Injury, H2 2015
Number of Products under Development for Brain Injury - Comparative Analysis, H2 2015
Number of Products under Development by Companies, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Early Stage Development, H2 2015
Products under Development by Companies, H2 2015
Products under Investigation by Universities/Institutes, H2 2015
Brain Injury - Pipeline by Acorda Therapeutics, Inc., H2 2015
Brain Injury - Pipeline by Biogen, Inc., H2 2015
Brain Injury - Pipeline by Chiesi Farmaceutici SpA, H2 2015
Brain Injury - Pipeline by Faron Pharmaceuticals Oy, H2 2015
Brain Injury - Pipeline by FibroGen, Inc., H2 2015
Brain Injury - Pipeline by Virogenomics, Inc., H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Stage and Target, H2 2015
Number of Products by Stage and Mechanism of Action, H2 2015
Number of Products by Stage and Route of Administration, H2 2015
Number of Products by Stage and Molecule Type, H2 2015
Brain Injury Therapeutics - Recent Pipeline Updates, H2 2015
Brain Injury - Dormant Projects, H2 2015
Brain Injury - Discontinued Products, H2 2015

List of Figures
Number of Products under Development for Brain Injury, H2 2015
Number of Products under Development for Brain Injury - Comparative Analysis, H2 2015
Number of Products under Investigation by Universities/Institutes, H2 2015
Comparative Analysis by Early Stage Products, H2 2015
Assessment by Monotherapy Products, H2 2015
Number of Products by Top 10 Targets, H2 2015
Number of Products by Stage and Top 10 Targets, H2 2015
Number of Products by Top 10 Mechanism of Actions, H2 2015
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2015
Number of Products by Top 10 Molecule Types, H2 2015

Note: Product cover images may vary from those shown
3 of 4

Acorda Therapeutics, Inc.
Biogen, Inc.
Chiesi Farmaceutici SpA
Faron Pharmaceuticals Oy
FibroGen, Inc.
Virogenomics, Inc.

Note: Product cover images may vary from those shown
4 of 4
Note: Product cover images may vary from those shown

PLEASE SELECT A FORMAT

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a single user license, allowing one specific user access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is a site license, allowing all users within a given geographical location of your organisation access to the product.

  • Quick Help: The report will be emailed to you. The report is sent in PDF format. This is an enterprise license, allowing all employees within your organisation access to the product.

HAVE A QUESTION?

If you have a more general question about our products please try our

FAQ SECTION

RELATED PRODUCTS from Db

Our Clients

  • Shire PLC.
  • GlaxoSmithKline PLC
  • Astrazeneca PLC
  • Roche Diagnostics Ltd.
  • H. Lundbeck A/S
  • Electrical Geodesics, Inc.